| | |
Per share
and accompanying common warrant |
| |
Per pre-funded warrant
and accompanying common warrant |
| |
Total
|
| |||||||||
合併公開発行価格
|
| | | $ | 0.43 | | | | | $ | 0.429 | | | | | $ | 10,000,000 | | |
保証割引と手数料(1)
|
| | | $ | 0.028 | | | | | $ | 0.028 | | | | | $ | 652,086 | | |
費用が差し引かれていない収益は私たちに
|
| | | $ | 0.402 | | | | | $ | 0.401 | | | | | $ | 9,347,913 | | |
| | |
Page
|
| |||
本募集説明書の副刊
について
|
| | | | S-1 | | |
前向き陳述
|
| | | | S-2 | | |
SUMMARY
|
| | | | S-3 | | |
THE OFFERING
|
| | | | S-10 | | |
RISK FACTORS
|
| | | | S-12 | | |
USE OF PROCEEDS
|
| | | | S-14 | | |
DILUTION
|
| | | | S-15 | | |
我々が提供する証券説明
|
| | | | S-16 | | |
UNDERWRITING
|
| | | | S-20 | | |
LEGAL MATTERS
|
| | | | S-24 | | |
EXPERTS
|
| | | | S-24 | | |
どこでもっと情報を見つけることができますか
|
| | | | S-24 | | |
引用統合
|
| | | | S-24 | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
どこでもっと情報を見つけることができますか
|
| | | | 2 | | |
引用統合
|
| | | | 3 | | |
前向き陳述に関する特別説明
|
| | | | 4 | | |
THE COMPANY
|
| | | | 5 | | |
RISK FACTORS
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
債務証券説明
|
| | | | 11 | | |
株式説明
|
| | | | 18 | | |
他の証券説明
|
| | | | 20 | | |
PLAN OF DISTRIBUTION
|
| | | | 22 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT(フェニルプロピルアミン) | | | 6歳以上のADHD治療 | | | January 2016 | | | May 2016 | |
複方XR-ODT(メチルピペラゾン) | | | 6歳から17歳までのADHD患者の治療 | | | June 2017 | | | September 2017 | |
|
普通株(または普通株に代わる事前融資権証)とセット株式承認証の1株公開発行価格
|
| |
|
| | | $ | 0.43 | | | |||
|
2022年3月31日までの1株当たり有形帳簿純価値
|
| | | $ | (0.66) | | | | | | | | |
|
は今回発行された1株当たり収益の増加によるものである
|
| | | $ | 0.43 | | | | | | | | |
|
今回の発売発効後の調整後の1株当たりの有形帳簿純価
|
| | | | | | | | | $ | (0.23) | | |
|
新規投資家の1株当たり希釈(1)(2)
|
| | | | | | | | | $ | (0.66) | | |
Name
|
| |
Number of
shares |
| |
Number of
pre-funded warrants |
| |
Number of
Warrants |
| |||||||||
Cantor Fitzgerald & Co.
|
| | | | 13,978,780 | | | | | | 1,137,500 | | | | | | 15,116,280 | | |
Cannaccord Genuity LLC
|
| | | | 7,527,034 | | | | | | 612,500 | | | | | | 8,139,534 | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | ||
Total
|
| | | | 21,505,814 | | | | | | 1,750,000 | | | | | | 23,255,814 | | |
| | | | | | | | | | | | |||||||||||
| | |
Per share
and accompanying common warrant |
| |
Per pre-funded warrant
and accompanying common warrant |
| |
Total
|
| | | | |||||||||
合併公開発行価格
|
| | | $ | 0.43 | | | | | $ | 0.429 | | | | | $ | 10,000,000 | | | | ||
保証割引と手数料
|
| | | $ | 0.028 | | | | | $ | 0.028 | | | | | $ | 652,086 | | | | ||
費用が差し引かれていない収益は私たちに
|
| | | $ | 0.402 | | | | | $ | 0.401 | | | | | $ | 9,347,913 | | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
どこでもっと情報を見つけることができますか
|
| | | | 2 | | |
引用統合
|
| | | | 3 | | |
前向き陳述に関する特別説明
|
| | | | 4 | | |
THE COMPANY
|
| | | | 5 | | |
RISK FACTORS
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
債務証券説明
|
| | | | 11 | | |
株式説明
|
| | | | 18 | | |
他の証券説明
|
| | | | 20 | | |
PLAN OF DISTRIBUTION
|
| | | | 22 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT(フェニルプロピルアミン) | | | 6歳以上のADHD治療 | | | January 2016 | | | May 2016 | |
複方XR-ODT(メチルピペラゾン) | | | 6歳から17歳までのADHD患者の治療 | | | June 2017 | | | September 2017 | |
Adzenys ER(フェニルプロピルアミン)経口懸濁剤 | | | 6歳以上のADHD治療 | | | September 2017 | | | February 2018 | |